Filing Flows › Wave Life Sciences (WVE) › Q3 2026
Wave Life Sciences (WVE) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 27, 2026
Wave Life Sciences (WVE) reported revenue of $13.2M for the third quarter 2026 (Q3 2026), +73% from a year earlier and +479% from the quarter before. Operating margin was -502.0%, net loss $61.9M (470.5% of revenue).
Wave Life Sciences, Q3 2026: revenue $13.2M (+73% year over year), operating margin -502.0%, net loss $61.9M, operating cash flow −$60.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.2M | +479% | +73% |
| Operating profit | −$66.0M | — | — |
| Net earnings | −$61.9M | — | — |
| Operating cash flow | −$60.1M | — | — |
What changed
Revenue was $13.2M in Q3 2026, up 73% year over year and up 479% from the previous quarter.
Operating costs exceeded revenue by $66.0M, an operating margin of -502.0%. Total costs grew 24% against revenue growth of 73%. The fastest-growing cost line was General & admin (+40%). The quarter ended with a net loss of $61.9M, narrower than the previous quarter's $69.4M loss.
Operating cash flow was −$60.1M. Non-cash charges added back $880K of depreciation and $10.3M of share-based compensation. Working capital and other items used $9.4M. Capital expenditures of $15K exceeded it, leaving free cash flow of −$60.2M.
Questions
What was Wave Life Sciences' revenue in the third quarter 2026?
Wave Life Sciences (WVE) reported revenue of $13.2M for the third quarter 2026 (Q3 2026), +73% from a year earlier and +479% from the quarter before.
Was Wave Life Sciences profitable in the third quarter 2026?
Operating loss was $66.0M (-502.0% of revenue) and net loss $61.9M.
Source: Wave Life Sciences 10-Q on SEC EDGAR.